Combination of Biomaterials and Extracellular Vesicles from Mesenchymal Stem-Cells: New Therapeutic Strategies for Skin-Wound Healing

Hard-to-heal chronic wounds associated with aging and high-prevalence pathologies, such as diabetes, are a global health problem. Therefore, it is necessary to advance effective treatments to accelerate wound healing. Among these potential treatments are new therapies based on mesenchymal stem cells...

Full description

Saved in:
Bibliographic Details
Published in:Applied sciences 2023-02, Vol.13 (4), p.2702
Main Authors: Pulido-Escribano, Victoria, Torrecillas-Baena, Bárbara, Dorado, Gabriel, Gálvez-Moreno, María Ángeles, Camacho-Cardenosa, Marta, Casado-Díaz, Antonio
Format: Article
Language:English
Subjects:
Aging
Angiogenesis
Biological products
Biomaterials
Biomedical materials
Care and treatment
Cell proliferation
Chemokines
Clinical trials
Cytokines
Diabetes
Diabetes mellitus
Extracellular matrix
Extracellular vesicles
Fibroblasts
Global health
Growth factors
Hair
Health aspects
Immunomodulation
Mesenchymal stem cells
Microorganisms
Physiology
Public health
Regenerative medicine
Skin
Stem cells
Tissue engineering
Transplantation
Tumors
Ulcers
Vesicles
wound dressings
Wound healing
Wounds and injuries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hard-to-heal chronic wounds associated with aging and high-prevalence pathologies, such as diabetes, are a global health problem. Therefore, it is necessary to advance effective treatments to accelerate wound healing. Among these potential treatments are new therapies based on mesenchymal stem cells (MSC) and their secretomes, including extracellular vesicles (EV). They have an important therapeutic potential for the treatment of chronic ulcers, due to their immunomodulatory activity, as well as their ability to induce angiogenesis, cell proliferation and cell migration. The use of MSC-derived EV in regenerative medicine involves cell-free therapies that decrease risks associated with cell therapies, such as the potential development of tumors. However, the short half-life of MSC-EV is a limitation for their clinical use. A therapeutic strategy to increase the regenerative efficiency of EV in wounds is to encapsulate them in biomaterials. The latter must protect and progressively release EV in damaged tissues, optimizing healing. Biomaterials that can be used include hydrogels. These, in addition to acting as a vehicle for sustained application of EV, can create favorable environments for wound healing. Thus, the aim of this review is to critically describe the latest advances in the development of such therapeutic strategies. It highlights the significance and clinical potential of these new therapies, as well as the need to develop clinical trials, to ascertain their performance.
ISSN:2076-3417
2076-3417
DOI:10.3390/app13042702